Table 6 |.
Polygenic risk scores and non-vascular outcomes
Outcometype | Outcome | T2D PRS decile | n Cases | n Controls | OR | 95%CI lower | 95%CI upper | P | P for linear trend |
---|---|---|---|---|---|---|---|---|---|
Non-vascular | Retinopathy | 0–10% | 792 | 4,533 | 1.00 | Ref | Ref | - | 3.1E-32 |
10–20% | 832 | 4,533 | 1.08 | 0.97 | 1.20 | 0.158 | |||
20–30% | 795 | 4,533 | 1.05 | 0.94 | 1.17 | 0.364 | |||
30–40% | 852 | 4,533 | 1.14 | 1.02 | 1.26 | 0.019 | |||
40–50% | 814 | 4,533 | 1.08 | 0.97 | 1.20 | 0.152 | |||
50–60% | 891 | 4,533 | 1.20 | 1.08 | 1.33 | 6.8E-04 | |||
60–70% | 901 | 4,533 | 1.25 | 1.13 | 1.39 | 3.1E-05 | |||
70–80% | 936 | 4,533 | 1.30 | 1.17 | 1.45 | 6.8E-07 | |||
80–90% | 1,031 | 4,533 | 1.47 | 1.33 | 1.63 | 2.2E-13 | |||
90–100% | 1,069 | 4,533 | 1.59 | 1.44 | 1.77 | 4.2E-19 | |||
Chronic kidney | 0–10% | 3,446 | 3,391 | 1.00 | Ref | Ref | - | 7.3E-06 | |
disease | 10–20% | 3,490 | 3,391 | 1.03 | 0.93 | 1.15 | 0.508 | ||
20–30% | 3,439 | 3,391 | 1.04 | 0.94 | 1.14 | 0.488 | |||
30–40% | 3,463 | 3,391 | 1.05 | 0.95 | 1.16 | 0.323 | |||
40–50% | 3,370 | 3,391 | 1.04 | 0.95 | 1.14 | 0.409 | |||
50–60% | 3,362 | 3,391 | 1.07 | 0.97 | 1.17 | 0.166 | |||
60–70% | 3,389 | 3,391 | 1.07 | 0.98 | 1.17 | 0.129 | |||
70–80% | 3,285 | 3,391 | 1.07 | 0.98 | 1.17 | 0.121 | |||
80–90% | 3,373 | 3,391 | 1.07 | 0.98 | 1.16 | 0.151 | |||
90–100% | 3,326 | 3,391 | 1.16 | 1.07 | 1.26 | 5.9E-04 | |||
Neuropathy | 0–10% | 2,176 | 3,814 | 1.00 | Ref | Ref | - | 7.9E-08 | |
10–20% | 2,193 | 3,814 | 1.03 | 0.96 | 1.11 | 0.436 | |||
20–30% | 2,217 | 3,814 | 1.07 | 0.99 | 1.15 | 0.075 | |||
30–40% | 2,218 | 3,814 | 1.06 | 0.99 | 1.15 | 0.110 | |||
40–50% | 2,217 | 3,814 | 1.05 | 0.98 | 1.13 | 0.192 | |||
50–60% | 2,293 | 3,814 | 1.11 | 1.03 | 1.20 | 0.006 | |||
60–70% | 2,261 | 3,814 | 1.10 | 1.02 | 1.18 | 0.014 | |||
70–80% | 2,253 | 3,814 | 1.10 | 1.02 | 1.19 | 0.009 | |||
80–90% | 2,265 | 3,814 | 1.11 | 1.03 | 1.19 | 0.007 | |||
90–100% | 2,377 | 3,814 | 1.21 | 1.12 | 1.30 | 9.7E-07 |
Genome-wide polygenic risk scores (gPRS) for T2D were generated in the MVP participants of European ancestry with T2D by calculating a linear combination of weights derived from the Europeans in the DIAMANTE Consortium using the prune and threshold method in PRSice-2 software (pruning r2 = 0.8, P = 0.05). The gPRSs were divided into deciles and the risk of T2D-related non-vascular outcomes was assessed using a logistic regression model using the lowest decile (0–10%) as the reference category, together with the potential confounding factors of age, gender, and the first 10 PCs of European ancestry. The decile-specific P-values are shown in the column labeled P. In a separate logistic regression analysis, the continuous PRS was set as the dependent variable together with age, gender, and the first 10 PCs, and the P-value for linear trend is shown in the column labeled P for linear trend. For chronic kidney disease, a CKD PRS (from CKDgen consortium) is included in the regression model as an additional covariate. T2D, type 2 diabetes; PRS, polygenic risk score; n Cases, number of cases with the respective non-vascular outcome; n Controls, number of unaffected controls for the respective non-vascular outcome; OR, odds ratio; CI, confidence interval.